Sunday, September 02, 2007

MRI Detects Ductal carcinoma in situ (DCIS) Better than Mammography

According to an article recently published in The Lancet, magnetic resonance imaging (MRI) more accurately detects ductal carcinoma in situ (DCIS) of the breast than mammography.
Cure rates for breast cancer have been improving; this progress has been attributed to screening practices and new treatment options. The earlier breast cancer is diagnosed, the better the prognosis. On the other hand, cure rates are low for cancer that has spread to distant sites in the body. Therefore, screening to detect breast cancer in its earliest stages will lead to the best chances of a cure. Ductal carcinoma in situ of the breast refers to a small cancer found in one of the ducts of the breast. There has been debate over whether DCIS is a true cancer or a pre-cancerous tumor that has the potential to spread. Overall, researchers have agreed that treatment for DCIS significantly reduces the risk of invasive breast cancer. There is still debate, however, about the best screening measure for DCIS. Researchers from Germany recently conducted a clinical trial to compare mammography and MRI for the detection of DCIS. This trial included 167 women with DICS who underwent both mammography and MRI prior to surgery. 92% of DCIS was detected by MRI compared with only 56% detected with mammography. Of all the high-grade (more aggressive) DCIS, nearly half were missed by mammography but MRI detected 98% --Click the title of this post to read the full article from its source--

Labels: , , , ,

Saturday, December 23, 2006

Revolutionary Breast Cancer Screening Device

A Utah company has come up with such a revolutionary new device for screening breast cancer that it's getting a rare government grant of almost three million dollars to continue development. Right now, this new screening and diagnostic device has everything going for it. It requires no compression, no squeezing of the breasts, no discomfort to the woman. And, it's radiation free. The National Institutes of Health is so impressed that it's giving a Utah company called Techniscan 2.8 million dollars a rare event, and one of NIH's largest small business grants. Why so much interest? This system allows the patient to comfortably lie face down. The breast is suspended in warm water while the ultrasound scanner rotates in a circle, producing detailed 3-D images. --Click the title of this post to read the full article from its source--

Labels: , ,

Veridex Receives FDA Approval for Breast Cancer Test Kit

Research and diagnostic technology company Immunicon on Friday announced that Johnson & Johnson subsidiary Veridex has received FDA approval to market its CellSearch Circulating Tumor Cell Kit, the Philadelphia Inquirer reports. CellSearch is aimed at earlier detection of metastatic breast cancer that has spread to other parts of the body, according to the Inquirer. CellSearch uses blood samples to identify and count tumor cells in the body (Loyd, Philadelphia Inquirer, 12/15). Immunicon has an agreement with Veridex to sell the test .--Click the title of this post to read the full article from its source--

Labels: , , , ,

Monday, December 18, 2006

Researchers Find Two Biomarkers With Potential To Predict Breast Cancer Spread

Expression of two different proteins taken from primary tumor biopsies is highly associated with spread of breast cancer to nearby lymph nodes, according to researchers who say this protein profile could help identify at an early stage those patients whose disease is likely to metastasize. In the December 15 issue of Cancer Research, the researchers say over-expression of one unidentified protein and under-expression of another is 88 percent accurate in identifying breast cancer that has spread in a group of 65 patients, compared to an analysis of lymph nodes and outcomes. If the predictive and diagnostic power of these proteins is validated, they could be analyzed in primary tumor biopsies that are routinely collected at the time of diagnosis, saving some women from extensive and possibly unnecessary treatment as well as from undergoing a second surgery to collect lymph nodes for analysis, the researchers say. --Click the title of this post to read the full article from its source--

Labels: , , ,

New Gamma Camera Technique For The Detection Of Small Breast Tumors

A diagnostic device that resembles a mammography unit can detect breast tumors as tiny as one-fifth of an inch in diameter, which may make it a valuable complementary imaging technique to mammography, say researchers at Mayo Clinic, who helped develop the technology along with industry collaborators Gamma Medica and GE Healthcare.This new technique, Molecular Breast Imaging, uses a new dual-head gamma camera system and is sensitive enough to detect tumors less than 10 millimeters (about two-fifths of an inch) in diameter in 88 percent of cases where it is used. Early findings from an ongoing comparison of the device with mammography show that it can detect small cancers that were not found with mammography, say the investigators. Mayo Clinic physicist Michael O’Connor, Ph.D., will present these results Saturday, Dec. 16, at the 2006 meeting of the San Antonio Breast Cancer Symposium.“Our ultimate goal is to detect small cancers that may be inconspicuous or invisible on a mammogram for high-risk women with dense breasts,” says Dr. O’Connor. --Click the title of this post to read the full article from its source--

Labels: , , ,

Saturday, December 16, 2006

New breast cancer scanner approved

A promising new breast scanning technology with none of the radiation dangers associated with mammograms has been approved for sale by Health Canada. Known as SoftScan, the device uses infrared lasers to detect and monitor malignancies, even in dense breast tissue that mammography can fail to penetrate. The new machine will not replace mammograms, which will continue to be the standard tool for pinpointing breast cancers for the foreseeable future, said Dr. Nathalie Duchesne, a professor of radiology at Quebec City's Laval University. "There are no side effects to this technology," said Duchesne, who has worked in clinical trials with SoftScan for nearly a decade and is a paid consultant for Advanced Research Technologies Inc., which makes the machines. --Click the title of this post to read the full article from its source--

Labels: , , , , ,

Thursday, November 30, 2006

Some breast cancer invisible to mammograms

You've heard the warnings about breast cancer - how early detection and annual mammograms can save your life. But, did you know there is a type of breast cancer that does not show up on standard tests? This type of breast cancer is an unknown killer. It's a no show on a mammogram. It's very aggressive, and if you are not paying attention to your body, you may not discover you have it until it is too late. --Click the title of this post to read the full article from its source--

Labels: , ,

Oncotype DX™ Contracts with Aetna

Aetna Health, one of the nation's largest health benefits companies, has formed an agreement with Genomic Health to establish pay rates for the use of Oncotype DX™. This agreement establishes payment rates for all of Aenta's plans for eligible members with early-stage breast cancer. Ultimately, this contract will cover an estimated 80 million people. Node-negative, early breast cancer refers to cancer that has not spread from the breast to other sites in the body, including lymph nodes under the arms. Although chemotherapy is recommended for many women with early-stage, node-negative breast cancer, the benefit of chemotherapy varies. Identifying in advance those women who are most likely to benefit from chemotherapy may allow for more individualized treatment. As a result, women who are unlikely to benefit from chemotherapy could avoid the unwanted side effects of treatment, while women who would benefit from chemotherapy could be treated accordingly. --Click the title of this post to read the full article from its source--

Labels: ,

/* WebRing Code */